Converium

Converium Dosage/Direction for Use

irbesartan

Manufacturer:

Medochemie

Distributor:

Medochemie
Full Prescribing Info
Dosage/Direction for Use
The usual recommended initial and maintenance dose is 150 mg once daily, with or without food.
Converium at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.
In patients insufficiently controlled with 150 mg once daily, the dose of Converium can be increased to 300 mg, or other anti-hypertensive agents can be added (see Pharmacology: Pharmacodynamics under Actions, Contraindications, Precautions and Interactions). In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Converium (see Interactions).
In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. The demonstration of renal benefit of Converium in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see Pharmacology: Pharmacodynamics under Actions).
Renal impairment: No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing hemodialysis. (see Precautions)
Intravascular volume depletion: volume and/or sodium depletion should be corrected prior to administration of Converium.
Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment.
Elderly patients: Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for the elderly.
Pediatric population: The safety and efficacy of Converium have not been established in children.
Method of administration: Oral administration.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in